Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
May 12, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 – - PKU program progressing with Phase 3 readiness activities underway – ...
May 05, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces First Quarter 2022 Conference Call and Webcast

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
April 28, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
April 26, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
April 01, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
March 17, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – - Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2...
March 10, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
March 03, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
February 24, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic To Present at Upcoming Investor and Industry Conferences

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right